Cargando…

Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist

PURPOSE: The purpose of this research work was to formulate raft-forming chewable tablets of H(2) antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. MATERIALS AND METHODS: Tablets were prepared by wet granulation and evaluated for raft strength, acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Prajapati, Shailesh T, Mehta, Anant P, Modhia, Ishan P, Patel, Chhagan N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618633/
https://www.ncbi.nlm.nih.gov/pubmed/23580933
http://dx.doi.org/10.4103/2230-973X.106988
_version_ 1782265432457084928
author Prajapati, Shailesh T
Mehta, Anant P
Modhia, Ishan P
Patel, Chhagan N
author_facet Prajapati, Shailesh T
Mehta, Anant P
Modhia, Ishan P
Patel, Chhagan N
author_sort Prajapati, Shailesh T
collection PubMed
description PURPOSE: The purpose of this research work was to formulate raft-forming chewable tablets of H(2) antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. MATERIALS AND METHODS: Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 2(3) full-factorial design was used in the present study for optimisation. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as independent variables. Raft strength, acid neutralisation capacity and drug release at 30 min were selected as responses. RESULTS: Tablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralisation capacity and in vitro drug release of all factorial batches were found to be satisfactory. The F(5) batch was optimised based on maximum raft strength and good acid neutralisation capacity. Drug–excipient compatibility study showed no interaction between the drug and excipients. Stability study of the optimised formulation showed that the tablets were stable at accelerated environmental conditions. CONCLUSION: It was concluded that raft-forming chewable tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease.
format Online
Article
Text
id pubmed-3618633
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-36186332013-04-11 Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist Prajapati, Shailesh T Mehta, Anant P Modhia, Ishan P Patel, Chhagan N Int J Pharm Investig Original Research Article PURPOSE: The purpose of this research work was to formulate raft-forming chewable tablets of H(2) antagonist (Famotidine) using a raft-forming agent along with an antacid- and gas-generating agent. MATERIALS AND METHODS: Tablets were prepared by wet granulation and evaluated for raft strength, acid neutralisation capacity, weight variation, % drug content, thickness, hardness, friability and in vitro drug release. Various raft-forming agents were used in preliminary screening. A 2(3) full-factorial design was used in the present study for optimisation. The amount of sodium alginate, amount of calcium carbonate and amount sodium bicarbonate were selected as independent variables. Raft strength, acid neutralisation capacity and drug release at 30 min were selected as responses. RESULTS: Tablets containing sodium alginate were having maximum raft strength as compared with other raft-forming agents. Acid neutralisation capacity and in vitro drug release of all factorial batches were found to be satisfactory. The F(5) batch was optimised based on maximum raft strength and good acid neutralisation capacity. Drug–excipient compatibility study showed no interaction between the drug and excipients. Stability study of the optimised formulation showed that the tablets were stable at accelerated environmental conditions. CONCLUSION: It was concluded that raft-forming chewable tablets prepared using an optimum amount of sodium alginate, calcium carbonate and sodium bicarbonate could be an efficient dosage form in the treatment of gastro oesophageal reflux disease. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3618633/ /pubmed/23580933 http://dx.doi.org/10.4103/2230-973X.106988 Text en Copyright: © International Journal of Pharmaceutical Investigation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Prajapati, Shailesh T
Mehta, Anant P
Modhia, Ishan P
Patel, Chhagan N
Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title_full Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title_fullStr Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title_full_unstemmed Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title_short Formulation and optimisation of raft-forming chewable tablets containing H(2) antagonist
title_sort formulation and optimisation of raft-forming chewable tablets containing h(2) antagonist
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618633/
https://www.ncbi.nlm.nih.gov/pubmed/23580933
http://dx.doi.org/10.4103/2230-973X.106988
work_keys_str_mv AT prajapatishailesht formulationandoptimisationofraftformingchewabletabletscontainingh2antagonist
AT mehtaanantp formulationandoptimisationofraftformingchewabletabletscontainingh2antagonist
AT modhiaishanp formulationandoptimisationofraftformingchewabletabletscontainingh2antagonist
AT patelchhagann formulationandoptimisationofraftformingchewabletabletscontainingh2antagonist